Literature DB >> 33554

Beta hemolytic streptococcal endocarditis: predominance of non-group A organisms.

D C Blair, D B Martin.   

Abstract

Identification of beta hemolytic streptococci (BHS) as group A or non-group A on the basis of bacitracin sensitivity rather than Lancefield serogrouping may lead to misidentification of the pathogen. In four recent cases of endocarditis due to BHS, the pathogens initially were identified as group A; Lancefield serogrouping showed all four to be group G. All four patients presented with a syndrome characteristic of acute bacterial endocarditis. Review of all cases of endocarditis at our institution for the past five years showed none due to group A BHS. In 166 previously reported cases of endocarditis due to BHS, 68 pathogens were serogrouped: 53 belonged to groups B, C, G, or H; only five were group A. Our four cases and review of the literature demonstrate the need for Lancefield serogrouping in serious beta hemolytic streptococcal infections, rather than reliance on bacitracin sensitivity.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 33554     DOI: 10.1097/00000441-197811000-00003

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  4 in total

1.  Two cases of osteomyelitis due to group G streptococcus.

Authors:  N Joshi; J N Goldman
Journal:  Can J Infect Dis       Date:  1990

2.  A case of disseminated infection caused by Streptococcus equi subspecies zooepidemicus.

Authors:  Marie-France Poulin; Guy Boivin
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

3.  Endophthalmitis as presenting symptom of group G streptococcal endocarditis.

Authors:  P E Verweij; A J Rademakers; P P Koopmans; J F Meis
Journal:  Infection       Date:  1994 Jan-Feb       Impact factor: 3.553

4.  Septicemia and endocarditis caused by group G streptococci in a Norwegian hospital.

Authors:  A Bucher; P Gaustad
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-04       Impact factor: 3.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.